Ischemia-modified albumin use as a prognostic factor in coronary bypass surgery

Creative Commons License

KANKO M., YAVUZ Ş., Duman C., Hosten T., Oner E., Berki T.

JOURNAL OF CARDIOTHORACIC SURGERY, cilt.7, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1186/1749-8090-7-3
  • Dergi Adı: JOURNAL OF CARDIOTHORACIC SURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Coronary artery bypass surgery, ischemia-modified albumine, myocardial ischaemia, COBALT-BINDING TEST, CREATINE KINASE-MB, MYOCARDIAL-ISCHEMIA, MARKER, RELEASE, DISEASE, REVASCULARIZATION, INTERVENTION, ANGIOPLASTY, INFARCTION
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Background: Various types of markers have been used so far in order to reveal myocardial perfusion defect. However, these markers usually appear in the necrosis phase or in the late stage. Having been the focus of various investigations recently, ischemia-modified albumin (IMA) is helpful in establishing diagnosis in the early stages of ischemia, before necrosis develops.